UBS Raises Pfizer, Inc. TP to USD30, Rating Neutral; Quarterly Results Beat Forecasts and Guidance Raised

LongbridgeAII'm LongbridgeAI. Here is the key information I extracted
- UBS reported that Pfizer, Inc. exceeded third-quarter expectations with USD 16.58 billion in revenue and USD 0.87 EPS, prompting management to raise full-year revenue guidance to USD 62 billion to USD 64 billion.
- The broker raised Pfizer, Inc.’s target price from USD 27 to USD 30 while maintaining a Neutral rating, citing improved core business stability despite upcoming patent expiry pressures.…
Disclaimer

UBS published a research report stating that Pfizer, Inc. (PFE.US) 's third-quarter results beat expectations, with quarterly revenue of USD16.58 billion, above market expectations of USD15.85 billion. EPS was USD0.87, higher than market expectations of USD0.73. Management raised full-year revenue guidance to between USD62 billion and USD64 billion, with the midpoint of guidance increased by USD1.5 billion from USD61.5 billion to USD63 billion. Multiple projects in the product pipeline continued to advance.

The broker believes the improved results will help stabilize the core business. However, the company still faces patent expiry pressure of about USD15 billion to USD20 billion over the next few years, and whether it can fill the patent gap through 2030 remains to be seen. It expects a key near-term catalyst to be the Phase III data for MEVPRO-1 in second-line metastatic castration-resistant prostate cancer in 1Q27.

The broker raised its TP on Pfizer, Inc. (PFE.US) from USD27 to USD30, corresponding to about 10x to 11x its 2027 EPS forecast, while maintaining a Neutral rating.(gc/da)(Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.